HEALTHY EXTRACTS INC. 10-Q

ITEM 1 Financial Statements HEALTHY EXTRACTS, INC. CONSOLIDATED BALANCE SHEETS (Unaudited) MARCH 31 DECEMBER 31, 2023 2022 ASSETS CURRENT ASSETS Cash $ 213,204 $ 65,651 Accounts receivable 135,398 105,794 Inventory 1,654,206 1,819,128 Total current assets 2,002,808 1,990,572 Fixed assets, net of accumulated depreciation of $ 44,709 and $ 45,474 , respectively 4,952 5,501 Patents/Trademarks 521,881 521,881 Deposit 16,890 16,890 Prepaid Acquisition Costs 85,632 53,015 Goodwill 193,260 193,260 Total other assets 822,614 790,546 TOTAL ASSETS $ 2,825,422 $ 2,781,118 LIABILITIES AND STOCKHOLDERS' DEFICIT LIABILITIES Accounts payable $ 114,485 $ 91,316 Accrued liabilities 85,871 94,554 Notes payable 487,445 275,370 Notes payable - related party 866 866 Convertible debt, net of discount of $0.00 and $0.00, respectively 595,638 317,284 Convertible debt - related party, net of discount of $0.00 and $0.00, respectively - - Accrued interest payable 39,023 21,387 Accrued interest payable - related party - - Derivative liabilities 186,919 102,011 Total current and total liabilities 1,510,248 902,788 STOCKHOLDERS' EQUITY (DEFICIT) Preferred stock, $ 0.001 par value, 75,000,000 shares authorized, none and none shares issued and outstanding, respectively - - Common stock, $ 0.001 par value, 2,500,000,000 shares authorized, 345,492,442 and 345,172,442 shares issued and outstanding, respectively 345,492 345,172 Additional paid-in capital 17,475,579 17,459,899 Accumulated deficit ( 16,505,898 ) ( 15,926,742 ) Total stockholders' equity (deficit) 1,315,174 1,878,330 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $ 2,825,422 $ 2,781,118 The accompanying notes are an integral part of these unaudited consolidated financial statements. 2 HEALTHY EXTRACTS, INC. CONSOLIDATED STATEMENT OF OPERATIONS FOR THE THREE MONTH ENDING MARCH 31, (Unaudited) FOR THE THREE MONTHS ENDING MARCH 31 2023 2022 REVENUE Gross revenue $ 614,943 $ 551,654 Net revenue 614,943 551,654 COST OF REVENUE Cost of goods sold 320,724 226,949 Written off inventory 16,378 - Total cost of revenue 337,102 226,949 GROSS PROFIT 277,841 324,705 OPERATING EXPENSES General and administrative 683,029 370,357 Total operating expenses 683,029 370,357 OTHER INCOME (EXPENSE) Interest expense, net of interest income ( 89,060 ) ( 32,957 ) Change in fair value on derivative ( 84,908 ) 78,978 Loss on extinguishment of debt - - SBA loan forgiveness - - Gain on sale of asset - 2,643 Total other income (expense) ( 173,968 ) 48,664 Net gain/(loss) before income tax provision ( 579,157 ) 3,011 NET GAIN/(LOSS) $ ( 579,157 ) $ 3,011 Loss per share - basic and diluted $ ( 0.00 ) $ 0.00 Weighted average number of shares outstanding - basic and diluted 342,514,810 313,764,817 The accompanying notes are an integral part of these unaudited consolidated financial statements. 3 HEALTHY EXTRACTS, INC. CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) FOR THE MONTHS ENDING MARCH 31, 2023 AND 2022 (Unaudited) Additional Preferred Stock Common Stock Paid-In Accumulated Shares Amount Shares Amount Capital Deficit Total Balance - December 31, 2021 - $ - 338,384,171 $ 338,384 17,075,974 $ ( 14,943,620 ) $ 2,470,738 Cancelation of common stock for debt - - ( 200,267 ) ( 200 ) ( 9,813 ) - ( 10,013 ) Issuance of common stock for cash - - 507,917 508 24,888 - 25,396 Cancelation of common stock for debt - - ( 600,000 ) ( 600 ) ( 43,200 ) - ( 43,800 ) Issuance of common stock for services - - 1,000,000 1,000 63,000 - 64,000 Issuance of common stock for services - - 1,000,000 1,000 56,100 - 57,100 Issuance of common stock for services - - 4,400,000 4,400 259,600 - 264,000 Issuance of common stock-Note Conversion - - 340,621 341 16,690 - 17,031 Issuance of common stock for services - - 340,000 340 16,660 - 17,000 Net (loss) gain for the period - - - - - ( 983,121 ) ( 983,121 ) Balance - December 31, 2022 - $ - 345,172,442 $ 345,172 17,459,899 $ ( 15,926,742 ) $ 1,878,330 Issuance of common stock for services - - 320,000 320 15,680 - 16,000 Net (loss) gain for the period - - - - - ( 579,157 ) ( 579,157 ) Balance - December 31, 2023 - $ - 345,492,442 345,492 17,475,579 ( 16,505,898 ) 1,315,174 The accompanying notes are an integral part of these financial statements. 4 HEALTHY EXTRACTS, INC. CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) FOR THE THREE MONTHS ENDING MARCH 31 2023 2022 Cash Flows from Operating Activities: Net Gain/(Loss) $ ( 579,157 ) $ 3,011 Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 549 ( 768 ) Warrants issued for services 16,000 - Non-cash compensation - - Change in fair value on derivative liability 84,908 ( 78,978 ) Loss on extinguishment of debt - - Gain on sale of asset - 2,643 Impairment of goodwill - - Changes in operating assets and liabilities: Accounts receivable ( 29,604 ) 24,169 Inventory 164,922 ( 50,558 ) Accrued interest receivable - - Deposits - ( 16,890 ) Accounts payable 23,170 68,153 Accounts payable - related party - - Accrued liabilities ( 8,683 ) ( 54,767 ) Accrued interest payable 17,636 ( 7,822 ) Accrued interest payable - related party - 3,400 Net Cash used in Operating Activities ( 310,259 ) ( 108,408 ) Cash Flows from Investing Activities: Purchase of fixed assets ( 0 ) ( 7,987 ) Cash received from sale of asset - - Purchase of note receivable - - Trademarks - - Payments of note receivable - - Cash flows provided by (used in) Investing Activities: ( 0 ) ( 7,987 ) Cash Flows from Financing Activities: Purchase of Hyperion/OP&M ( 32,617 ) - Proceeds from issuance of common stock - ( 28,417 ) Proceeds from issuance of convertible debt 167,819 202,000 Payments for repayment of convertible debt 110,535 ( 167,000 ) Proceeds from issuance of noted payable 136,705 - Payments for repayment of notes payable 75,370 - Proceeds from issuance of noted payable - related party - ( 20,000 ) Net Cash provided by Financing Activities 457,812 ( 13,417 ) Increase (decrease) in cash 147,553 ( 129,812 ) Cash at beginning of period 65,651 222,098 Cash at end of period $ 213,204 $ 92,286 The accompanying notes are an integral part of these unaudited consolidated financial statements. 5 HEALTHY EXTRACTS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 and 2022 NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Healthy Extracts Inc. (the “Company”) was incorporated in the State of Nevada on December 19, 2014 as Grey Cloak Tech Inc. On October 23, 2020, we changed our name from Grey Cloak Tech Inc. to Healthy Extracts Inc. to more accurately reflect our business. The Company has acquired BergaMet NA, LLC and Ultimate Brain Nutrients, LLC which market and sell health supplemental products. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2023 and the results of operations and cash flows for the periods presented. The results of operations for the months ending March 31, 2023 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s form 10-K for the year ended December 31, 2022 filed with the SEC on March 31, 2023. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments. In regards to inventory write-offs and allowances, our Company policy is to review all expiration dates for all our products, at a minimum quarterly. If a product is within twelve months of expiration we will discuss if this amount of product will be sold within those months. If we have a surplus of product over the twelve month demand, we will write-off the additional amount during the current reporting period. If we have any damaged or unsellable inventory items, we will automatically write-off those items in the current month report period. As for revenue adjustments for discounts, allowances and refunds, we treat each of these items differently. When it comes to revenue discounts, we will create the invoice for the product sold which will include any discounts given. These discounts usually happen for a short period of time for sales that we will offer around holidays. Due to the revenue being recognized once the order has shipped, less any applicable discount, we book this transaction at the net order transaction amount. In regards to allowances and refunds for revenue adjustments, due to our refund percentage is less than 1% we decided the need for an estimated adjustment for allowances and refunds was not material. If we do receive any returned orders, we will directly book those orders as refunds the day we receive the call from the customer requesting the refund. We will book the credit memo at the full value of the customer original order. Cash Cash includes cash in banks, money market funds, and certificates of term deposits with maturities of less than three months from inception, which are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss in value. 6 Accounts Receivables Accounts receivables are recorded at the invoice amount and do not bear interest. Inventory Inventories consist of health supplements held for sale in the ordinary course of business. The Company uses the weighted average cost method to value its inventories at the lower of cost and net realizable value. The components of inventory cost include raw materials, labor, and overhead. Net realizable value is determined using various assumptions with regard to excess or slow-moving inventories, expiration dates, current and future product demand, production planning, and market conditions. A change in any of these variables could result in an adjustment to inventory. An allowance for inventory was established in 2018 and is evaluated each quarter to determine if all items are still sellable due to expiration dates. As of March 31, 2023 and 2022, the total of inventory which was written off as an inventory allowance was $ 1,914,891 and $ 1,914,891 . MARCH 31, MARCH 31, 2023 2022 Inventory Inventory Classes: Raw Materials $ 1,313,407 $ 1,571,458 Finished Goods 317,493 330,848 Work in process 23,306 106,218 Total inventory 1,654,206 2,008,524 Property and Equipment The Company’s property and equipment are recorded at cost and depreciated using the straight-line method over the useful lives of the assets, generally from three to seven years. Upon sale or disposal of property and equipment, the related asset cost and accumulated depreciation or amortization are removed from the respective accounts and any gain or loss is reflected in current operations. Indefinite-Lived Intangible Assets Indefinite-lived intangible assets established in connection with business combinations consist of patents, trademarks, and trade names. The impairment test for identifiable indefinite-lived intangible assets consists of a comparison of the estimated fair value of the intangible asset with its carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. With the acquisition of Ultimate Brain Nutrients on April 3, 2020 the Company added a purchasing value of $ 315,604 in patents to its balance sheet. As of March 31, 2023, the Company believes that based upon qualitative factors, no impairment of indefinite-lived intangible assets is necessary. Goodwill In accordance with Goodwill and Other Intangible Assets, goodwill is defined as the excess of the purchase price over the fair value assigned to individual assets acquired and liabilities assumed and is tested for impairment at the reporting unit level on an annual basis in the Company's fourth fiscal quarter or more frequently if indicators of impairment exist. The performance of the test involves a two-step process. The first step of the impairment test involves comparing the fair value of the Company's reporting units with each respective reporting unit's carrying amount, including goodwill. The fair value of reporting units is generally determined using the income approach. If the carrying amount of a reporting unit exceeds the reporting unit's fair value, the second step of the goodwill impairment test is performed to determine the amount of any impairment loss. The second step of the goodwill impairment test involves comparing the implied fair value of the reporting unit's goodwill with the carrying amount of that goodwill. The Company sees the goodwill to have a ten-year useful life. No goodwill impairment indicators were present, for the goodwill listed on the books as of March 31, 2023, after working through our analysis of goodwill during the months ending March 31, 2023. 7 The Company has determined that the method applied represents the fair value of the asset group principally because the valuation of the intangibles with the asset group is based on the anticipated cash flows related to the revenue stream from its customers. The asset group excludes goodwill, long term non-operational assets and liabilities and cash. As such, the principal value from the asset group relates to the cash inflows from its customers and the cash outflows required to service these customers. The fair value for the asset group consists of the following: · Fair value of net revenues: computed using the income approach. The key input to these computations is the anticipated cash inflows from customers. These valuations include 100% of the cash inflows related to the customer base, and taking cash outflows into consideration. · Fair value of working capital (including accounts receivable, inventory, accrued expenses, and accounts payables). Due to the short-term nature of the working capital, book value has been determined to be fair value. These accounts represent either avoided future outflows (inventory, prepaids) or future cash flows (accrued expense, AP and AR) related to customer sales. · Fair value of five years of revenue (2022 to 2026): we discounted our cash flows to the anticipated cash projected to be received. We also projected the anticipated cash outflows required to service these customers. If the asset group was to be valued as a whole, we would expect an income approach based on the revenues being generated from the customers and expenses required to service those customers, appropriately adjusted for the working capital position. The sum of these values reasonably approximates this approach. The Company’s revenue streams align directly with the intangibles, which were recorded as a result of the BergaMet acquisition in fiscal 2019. For purposes of the Step 2 recoverability test under ASC 360 subsection 2.3., the net revenues from BergaMet customers base were used. The revenue stream fairly reflects anticipated future cash flows; accordingly, the intangibles associated with these revenue streams have been tested with the expected cash flows. Due to the purchase of Ultimate Brian Nutrients, LLC being a related party transaction and the new division recording no revenue as of June 30, 2020, the Company found the goodwill to be impaired. Due to the impairment the Company expensed the goodwill related to the purchase as of June 30, 2020. Revenue Recognition The Company applies Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) topic 606, Revenue from Contracts with Customers (ASC 606). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes all of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 requires us to identify distinct performance obligations. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. When distinct performance obligations exist, the Company allocates the contract transaction price to each distinct performance obligation. The standalone selling price is used to allocate the transaction price to the separate performance obligations. The Company recognizes revenue when, or as, the performance obligation is satisfied. Generally, revenues are recognized at the time of shipment to the customer with the price being fixed and determinable and collectability assured, provided title and risk of loss is transferred to the customer. Most of our shipping and handling costs are built into the transaction price, but if the customer asks for express shipping, the costs charged to customers are classified as sales, and the shipping and handling costs incurred are included in cost of sales. The Company’s subsidiary, BergaMet N.A., LLC, recognizes revenue from our main source – e-commerce revenue. Here is a list of all the sales channels which include the Company’s subsidiary website channel or any other selling channel like Amazon, doctors’ offices, and walk-in sales. All of our customer sales for Healthy Extracts, Inc. and Ultimate Brain Nutrients, LLC are recognized as revenue under the subsidiary of BergaMet N.A., LLC. All three divisions of the Company sell plant-based nutraceuticals to our end using customers. The Company evaluates the criteria outlined in ASC 606-10-55, Principal versus Agent Considerations, currently we are the principal and have not engaged an agents at this time. Currently, we have not recognize any revenues under the agent considerations. 8 Revenue is recognized when, or as, control of a promised merchandise or service is shipped to the customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring title of those products or services and are recorded net of and discounts or allowances. Shipping costs paid by the customer are included in revenue. Merchandise sales are fulfilled with inventory held in our warehouse in Henderson, NV. Therefore, the Company’s contracts have a single performance obligation (shipment of product). If the Company receives a request for refund on a customer obligation, the Company will refund the full cost of the obligation due to our money back guarantee. Revenue recognition is evaluated through the following five-step process: 1. identification of the contract with a customer; 2. identification off the performance obligations in the contract; 3. determination of the transaction price; 4. allocation of the transaction price to the performance obligations in the contract; and 5. recognition of revenue when or as a performance obligation is satisfied. These steps are met when an order is received, a price agreed and the product shipped or delivered to that customer. Concentration There is no concentration of revenue for the months ended March 31, 2022 and for the months ended March 31, 2023 because the revenue was earned from multiple customers. Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “Accounting for Income Taxes”. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities and for operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. For the period ending March 31, 2022 and March 31, 2023, the Company did not have any amounts recorded pertaining to uncertain tax positions. The following is accounting our operating loss carry-forward since our inception: NOL Carryforward: Year Total Balance Est Tax Benefit 2014 (Estimated Tax Rate 15%) $ ( 19,500 ) $ ( 19,500 ) ( 2,925 ) 2015 (Estimated Tax Rate 15%) ( 730,872 ) ( 750,372 ) ( 109,631 ) 2016 (Estimated Tax Rate 15%) ( 3,370,935 ) ( 4,121,307 ) ( 505,640 ) 2017 (Estimated Tax Rate 15%) ( 3,562,075 ) ( 7,683,382 ) ( 534,311 ) 2018 (Estimated Tax Rate 21%) ( 3,329,517 ) ( 11,012,899 ) ( 699,199 ) 2019 (Estimated Tax Rate 21%) 632,776 ( 10,380,123 ) 132,883 2020 (Estimated Tax Rate 21%) ( 2,576,375 ) ( 12,956,498 ) ( 541,039 ) 2021 (Estimated Tax Rate 21%) ( 1,987,122 ) ( 14,943,620 ) ( 417,296 ) 2022 (Estimated Tax Rate 21%) ( 983,122 ) ( 15,926,742 ) ( 206,456 ) 2023 (Estimated Tax Rate 21%) ( 579,157 ) ( 16,505,899 ) ( 121,623 ) Total of NOL Carryforward ( 16,505,899 ) ( 3,005,237 ) Most of the net operating loss carry-forward has been created through continuing operations. In 2020, the Company wrote-off $1.58M due to the goodwill impairment from the purchase of Ultimate Brain Nutrients, LLC. If we use the highest federal tax rate from 2022 and 2021 of 21% we would have a tax benefit, due to the net operating loss carry-forward of ($ 2,883,614 ) and ($ 2,677,158 ) respectively. Due to being a Nevada corporation, we don’t have any state taxes due. Pursuant to Sec. 172(b)(3) of the Internal Revenue Code, the Company relinquish the entire carryback period with respect to the net operating loss incurred for the tax year ended above, and will have such losses available for carryforward only due to the negative earnings. All of the above listed carryforward balances will be subject to the carryover limit of 80% to offset future earnings for up to 20 years. Fair Value Measurements 9 The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The estimated fair value of certain financial instruments, including cash and cash equivalents are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions) The derivative liability in connection with the conversion feature of the convertible debt, classified as a Level 3 liability, is the only financial liability measure at fair value on a recurring basis. The change in Level 3 financial instrument is as follows: Balance, January 1, 2023 $ 102,011 Issued during the months ended March 31, 2023 133,031 Change in fair value recognized in operations ( 48,123 ) Converted during the months ended March 31, 2023 ( 0 ) Balance, March 31, 2023 $ 186,919 Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 amends the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements of five–step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract cost, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The amendments in this ASU are effective for reporting period beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company’s revenues are recognized when control of the promised goods or services is transferred to our clients (upon shipment of goods) in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: (1) Identify the contract with a client; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to performance obligations in the contract; and (5) Recognize revenues when or as the Company satisfies a performance obligation. We adopted ASC 2014-09 on January 1, 2019. Although the new revenue standard is expected to have an immaterial impact, if any, on our ongoing net income, we did implement changes to our processes related to revenue recognition and the control activities with them. Convertible Instruments The Company evaluates and account for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the 10 embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, any discounts, if applicable, to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts, if applicable, under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities. During the months ended March 31, 2023, the Company issued $ 388,888 of convertible debt with a bifurcated conversion option. The convertible debt which has been issued, was issued as a financial instrument with no floor to the liability. Due to this fact, for every reporting period we mark each instrument to the current market rate. We currently use the Black-Scholes option pricing model in order to calculate what the current market rate is for each instrument. Please see Note 7 for any further information on the value of each convertible debt instrument. Common Stock Purchase Warrants The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 (“Contracts in Entity's Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification is required. NOTE 3 – GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has generated minimal revenues from operations. Since its inception, the Company has been engaged substantially in financing activities and developing its business plan and incurring startup costs and expenses. As a result, the Company incurred accumulated net losses from Inception (December 19, 2014) through the period ended March 31, 2023 of $ 16,505,898 . Due to our negative cash flow, the Company has substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. In addition, the Company’s development activities since inception have been financially sustained through equity financing. Management plans to keep seeking funding through debt and equity financing which are intended to mitigate the conditions that have raised substantial doubt about the entity’s ability to continue as a going concern. NOTE 4 – RELATED PARTY For the months ended March 31, 2023 and 2022, the Company had expenses totaling $ 0 and $ 1,000 respectively, to an officer and director for salaries, which is included in general and administrative expenses on the accompanying statement of operations. As of March 31, 2023, there was a total of convertible debt of $0.00 and accrued interest payable of $0.00 due to an officer and director, employees, and shareholders. 11 NOTE 5 – LEASES The company leases warehouse facilities under an operating lease that expires in 2025. Prior to February 4, 2022 the company was leasing a warehouse facility on a month-to-month lease. The aggregate minimum future non-cancelable lease commitments at March 31, 2023 are as follows: 2023 $ 51,169 2024 $ 70,883 2025 $ 5,926 Total $ 144,851 Total rent expense for the months ended March 31, 2023 and 2022 was $ 16,873 and $ 15,370 . NOTE 6 – NOTES PAYABLE As of March 31, 2023, the Company had the following: Unsecured debt with a principal amount of $866 with shareholders of the Company, no due date, 0 % interest, 866 Unsecured debt with a principal amount of $330,000, due 8/20/24, 10 % interest, Late fee of the greater of $500 or 1% of the amount of the late payment, plus accrued and unpaid interest. 330,000 TOTAL $ 330,866 As of March 31, 2023, the Company has an outstanding total of $ 14,214 in interest accrued for the above notes. NOTE 7 – CONVERTIBLE DEBT As of December 31, 2022, the Company had the following: Unsecured convertible debt with a principal amount of $6,750, due 01/19/17 , 8 % interest, default interest at 18 %, converts at a 54% discount to market price based on the lowest trading prices in the last 20 days trading price 6,750 Unsecured convertible debt with a principal amount of $200,000, due 05/01/23 , 12 % interest, converts at a market price of $0.05 per share. 200,000 Unsecured convertible debt with a principal amount of $388,888, due 10/24/23 , 0 % interest, converts at the election of the holder at means ninety percent (90%) of the lowest VWAP of our common stock for the five (5) consecutive Trading Days immediately preceding the date of the issuance of a Conversion Election. 388,888 SUBTOTAL 595,638 Less: Discount - TOTAL $ 595,638 Below represent the Black-Scholes Option Pricing Model calculations for the above convertible note payables: Payee Number of options valued Value of Convertible Option Unsecured Convertible debt #1 373,686 $ 8,144 Unsecured Convertible debt #2 4,424,000 $ 45,744 Unsecured Convertible debt #3 5,555,540 $ 133,031 As of March 31, 2023, the Company has an outstanding total of $ 21,200 in accrued interest for the above convertible note. The convertible promissory notes #1 is in default but management has not been able to make contact with this party, due to them living out of the country. We have calculated the derivative liability as if it is in default (but the note’s default interest rate stays the same at 8%) and will still accrue appropriate interest until the note is fully satisfied or converted into the Company’s common stock. 12 The Company has determined that the conversion feature embedded in the notes referred to above that contain a potential variable conversion amount constitutes a derivative which has been bifurcated from the note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt. NOTE 8 – STOCKHOLDERS’ EQUITY Authorized Stock The Company has authorized 75,000,000 common shares with a par value of $ 0.001 per share. Each common share entitles the holder to one vote on any matter on which action of the stockholders of the corporation is sought. During February 2017, the Company increased the authorized number of shares to 500,000,000 . Also, the Company increased the authorized preferred stock to 75,000,000 shares and designated 25,000,000 shares of preferred stock to Series A Convertible Preferred Stock. During January 2018, the Company increased its authorized number of common shares to 1,000,000,000 . During April 2018, the Company increased its authorized number of common shares to 2,500,000,000 . The Board of Directors, in the future, has the authority to increase the authorized capital up to 4,000,000,000 shares based on shareholder approval. The Company effectuated a reverse stock split of 1-for-250 as of July 23, 2018 . On October 16, 2017, the Company filed an Amended and Restated Certificate of Designation of the Rights, Preferences, Privileges and Restrictions of the Series A Convertible Preferred Stock (the “Amended Certificate”) with the Secretary of State of the State of Nevada. The Amended Certificate reduces the number of preferred shares designated as Series A Preferred Stock from 25,000,000 shares to 1,333,334 shares. The Amended Certificate also changes the conversion and voting rights of the Series A Preferred Stock. The Series A Preferred Stock is now convertible into the number of shares of our common stock equal to 0.00006% of our outstanding common stock upon conversion. The voting rights of the Series A Preferred Stock are now equal to the number of shares of common stock into which the Series A Preferred Stock may convert. As of March 31, 2023, there are no outstanding shares of preferred stock. All the preferred stock was converted in common stock on February 4, 2019. Common Share Issuances During the months ended March 31, 2023, the Company issued 320,000 shares of common stock. On March 6, 2023, the Company issued 320,000 shares of common stock for consulting fees. There were no shares issued during the fourth quarter 2022. During the third quarter 2022, , the Company issued 340,000 shares of common stock for consulting fees along with issuing 340,621 shares of common stock to convert an outstanding note payable to a shareholder. On May 19, 2022, the Company issued 4,400,000 shares of common stock for broker and consulting fees. On April 22 and 25, 2022, the Company issued 2,000,000 shares of common stock for broker and funding fees. On February 4, 2022, the Company issued 507,917 shares of common stock in a direct security purchase agreement. On January 10, 2022, the Company cancelled 200,267 shares of common stock. Further, on March 4, 2022, the Company cancelled 600,000 shares of common stock. Warrant Issuances During the month ending March 31, 2022, the Company issued 7,421,544 warrants to 2 parties at a par share price of $0.04716. On February 2, 2022, the Company issued 2,000,000 warrants to an individual. As of March 31, 2023, there were 23,421,544 warrants outstanding, of which 20,600,000 warrants are fully vested. Stock Issued for Services On March 6, 2023, the Company issued 320,000 shares of common stock for consulting fees. On September 13, 2022, the Company issued 340,000 shares of common stock for consulting fees. During the period ending June 30, 2022, the Company issued 6,400,000 shares of common stock for broker, consulting, and funding fees. Share Conversion Agreements 13 All of the holders of the Company’s Series A Convertible Preferred Stock (the “Preferred Holders”) entered into a Preferred Stock Conversion Agreement. Pursuant to the Conversion Agreements, the Preferred Holders converted their shares of preferred stock into common stock, effective as of the Exchange. As a result, no shares of the Company’s Series A Convertible Preferred Stock are outstanding. An aggregate of 15,592,986 shares of common stock were issued to the Preferred Holders. The Preferred Holders agreed to convert each share of Series A Convertible Preferred Stock into eighteen (18) shares of common stock and agreed to retire a total of 467,057 shares of Series A Convertible Preferred Stock. The Company cancelled the retired shares. Omnibus Stock Grant and Option Plan On December 31, 2021, the Company approved stock option agreements in the amount of 7,500,000 shares with a strike price of $0.05 to twenty-one individuals. On December 26, 2022, the Company canceled 12,150,000 stock options with a strike price of $0.05. On the same date, the Company approved an equity incentive plan. Under this plan the company approved a total of 15,975,000 of restricted stock units and 36,000,000 of restricted stock awards with a strike price of $0.00 to $0.01 to sixteen individuals. Offering Circular During the first part of the 2021, the Company filed a Regulation A Offering Circular with the U.S. Securities and Exchange Commission. The Offering Circular was qualified during August 2021. NOTE 9 – BUSINESS SEGMENT INFORMATION As of March 31, 2023, the Company operated in two reportable segments (Corporate and Health Supplements) supported by a corporate group which conducts activities that are non-segment specific. The following table presents selected financial information about the Company’s reportable segments for the quarter March 31, 2023. CONSOLIDATED HEALTH SUPPLEMENTS CORPORATE BergaMet UBN Revenue 614,943 614,943 - - Cost of Revenue 337,102 337,102 - - Long-lived Assets 732,030 229,304 502,727 - Gain (Loss) Before Income Tax ( 579,157 ) ( 203,549 ) ( 813 ) ( 374,794 ) Identifiable Assets 1,654,206 1,654,206 - - Depreciation and Amortization 549 549 - - As of March 31, 2022, the Company operated in two reportable segments (Corporate and Health Supplements) supported by a corporate group which conducts activities that are non-segment specific. The following table presents selected financial information about the Company’s reportable segments for the quarter ended March 31, 2022. CONSOLIDATED HEALTH SUPPLEMENTS CORPORATE BergaMet UBN Revenue 551,654 551,654 - - Cost of Revenue 226,949 226,949 - - Long-lived Assets 732,030 229,304 502,727 - Gain (Loss) Before Income Tax 3,011 ( 19,171 ) ( 663 ) 22,846 Identifiable Assets 2,008,524 2,008,524 - - Depreciation and Amortization 768 768 - - Currently, all of our customers are located in the United States of American and Canada. Our revenues to our customers are not material to our overall total sales. Our largest customers, Natural Grocers and Emerson Ecologics, LLC, account for less than 1% of our total sales in the months ending 2023 and 2022. 14 NOTE 10 – SUBSEQUENT EVENTS COVID-19 On March 11, 2020, the World Health Organization declared the novel strain of coronavirus (COVID-19) a global pandemic and recommended containment and mitigation measures worldwide. The Company is monitoring this closely, and although operations have not been materially affected by the coronavirus outbreak to date, the ultimate severity of the outbreak is uncertain. Further the uncertain nature of its spread globally may impact our business operations resulting from quarantines of employees, customers, and third-party service providers. At this time, the Company is unable to estimate the impact of this event on its operations. On January 13, 2023 the Company entered into definitive agreement to acquire nutraceutical manufacturer, Hyperion, and its digital marketing affiliate, Online Publishing and Marketing. The total purchase price for the acquisitions will be $1,750,000 in cash, $1,300,000 in the form of secured promissory notes, and $1,250,000 worth of our common stock. The Company evaluated its March 31, 2023 financial statements for subsequent events through April 14, 2023, the date the financial statements were available to be issued. 15